Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics Net Debt / EBITDA

The Net Debt to EBITDA of Aspira Pathlab & Diagnostics (540788.BO) as of Oct 28, 2026 is 0.30. In the previous year, Net Debt to EBITDA was -1.18 — a change of -125.34% (higher).

Net Debt / EBITDA

0.30

YoY

-125.34%

Last updated:

Net Debt to EBITDA of Aspira Pathlab & Diagnostics is 2025 0.30 . Net Debt to EBITDA of Aspira Pathlab & Diagnostics was 2024 -1.18 . It decreases by -125.34% higher compared to the previous year.

The Aspira Pathlab & Diagnostics Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-2.87 INR
Jan 1, 2019
-2.31 INR
Jan 1, 2020
-3.78 INR
Jan 1, 2021
0.26 INR
Jan 1, 2022
0.36 INR
Jan 1, 2023
0.61 INR
Jan 1, 2024
-1.18 INR
Jan 1, 2025
0.30 INR
The Aspira Pathlab & Diagnostics Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.30-125.34%
-1.18-294.62%
0.61+69.29%
0.36+40.05%
0.26-106.76%
-3.78+63.56%
-2.31-19.70%
-2.87+65.33%
-1.74-115.34%
11.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aspira Pathlab & Diagnostics Stock analysis

What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics Ltd generates revenue through pathology investigation services, radiology investigation services, and health packages at its diagnostic centers in Mumbai. The company offers specialized tests such as the Shanti Screening Test, COVID-19 Antibody Test, and COVID-19 RT-PCR Test, which are part of its diagnostic services portfolio. Customers include individuals seeking health screenings, patients requiring medical diagnostics, and healthcare providers who refer clients to its facilities. The firm's services are segmented into pathology, radiology, and health packages, with a focus on high-demand tests like COVID-19 detection profiles. The company's revenue streams are derived from conducting various pathological investigations across branches like biochemistry, hematology, and microbiology. Its health packages and pathology tests, including the COVID-19 Detection Profile 1 and 2, cater to both individual and institutional clients. The firm operates within the healthcare sector, providing diagnostic solutions for patients and medical professionals in Mumbai, with a particular emphasis on pandemic-related testing services during the global health crisis. Aspira Pathlab & Diagnostics Ltd monetizes its diagnostic capabilities through a mix of routine pathology services and specialized health packages. The Shanti Screening Test and other COVID-19-related tests form a significant portion of its revenue, especially during periods of high demand for pandemic testing. The company serves a broad customer base, including individuals, clinics, and hospitals that rely on its diagnostic expertise for accurate medical assessments. Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspira Pathlab & Diagnostics stock

Net Debt to EBITDA of Aspira Pathlab & Diagnostics is 0.30 in 2025.

Net Debt to EBITDA of Aspira Pathlab & Diagnostics changed from -1.18 to 0.30, representing a -125.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Aspira Pathlab & Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Aspira Pathlab & Diagnostics

All Key Metrics — Aspira Pathlab & Diagnostics